The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination

AIDS

Volumn 17, Issue 7, 2003, Pages 1096-1099

  Duran, Ségolène ^a   Peytavin, Gilles ^b   Carrieri, Patrizia ^a   Raffi, François ^c   Ecobichon, Jean Luc ^b   Pereira, Edwige ^a   Cassuto, Gilles Patrice ^d   Spire, Bruno ^a   Leport, Catherine ^b  

^a INSERM   (France)

^b Faculté Bichat   (France)

^c HÔTEL DIEU   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INDINAVIR; M 8; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SELF ADMINISTRATION; FOLLOW UP; FRANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RELIABILITY; RISK; SELF REPORT; STATISTICAL ANALYSIS; VIRUS DETECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; QUESTIONNAIRES; SELF DISCLOSURE; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 0037541190     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00025     Document Type: Article

References (13)

1. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13:1099-1107.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
3. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
4. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
5. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Reader 2000; 10:177-185.
6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977.
7. Carrieri P, Caillilleton V, Le Moing V, Spire B, Dellamonica P, Bouvet, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO Cohort. J Acquir Immune Defic Syndr 2001; 28:232-239.
8. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24:123-128.
9. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet J-G, Costagliola D, et al. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 Cohort Study. AIDS 2001; 15:1075-1077.
10. Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161:1962-1968.
11. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 (Suppl. 2):S151-159.
12. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, SEI-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents SChemother 1998; 42:2784-2791.
13. Regazzi MB, Villani P, Maserati R, Cocchi L, Giacchino R, Burroni D, Rettani M. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol 1999; 47:379-382.